Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2011 Apr;17(2):110-7.
doi: 10.1111/j.1755-5949.2011.00234.x.

Treatment strategies for dosing the second generation antipsychotics

Thomas L Schwartz  1 , Stephen M Stahl
Affiliations
Review

Treatment strategies for dosing the second generation antipsychotics

Thomas L Schwartz et al. CNS Neurosci Ther. 2011 Apr.

Abstract

Background: The second generation antipsychotics now have clinical approvals for the treatment of schizophrenia, bipolar depression, bipolar mania, autism, major depressive disorder and are used furthermore off-label to treat other mental disorders. Each agent is unique in its pharmacodynamic profile and allows for unique dosing strategies to be employed when treating these different disorders.

Aims: To review relevant data regarding the second generation antipsychotics and their empirical dosing strategies. To further review and comment theoretically in these areas where substantial, definitive data are lacking.

Materials and methods: A MEDLINE and recent textbook review was conducted regarding each second generation antipsychotic and cross-referenced with searches for major mental disorders. The findings are compiled in the review below.

Discussion: The second generation antipsychotics are clearly delineated in the treatment of psychosis and mania and share similar mechanisms of action to achieve these results: dopamine-2 receptor antagonism for efficacy and serotonin-2a receptor antagonism for EPS tolerability. From here, each agent has a unique pharmacodynamic and pharmacokinetic profile where some agents carry more, or less antidepressant, anxiolyic, or hypnotic profiles. Choosing an agent, and dosing it in low, middle, or high ranges may result in differential effectiveness and tolerability.

Conclusion: The second generation antipsychotics have many clinical applications in psychiatric practice. This article serves to review this and also suggests ways clinicians may optimize treatment based upon patient diagnosis and utilizing appropriate dosing of each individual second generation antipsychotic.

PubMed Disclaimer

Conflict of interest statement

Thomas L. Schwartz, MD, is an associate professor of psychiatry at Upstate Medical University and has served as a Consultant to PamLab. He has served on speakers bureaus for Pfizer Inc; Wyeth Pharmaceuticals, AstraZeneca, and Merck pharmaceuticals and received research and/or grant support from Cephalon, Forest, Cyberonics.

Stephen M. Stahl, MD, PhD, is an adjunct professor of psychiatry at the University of California, San Diego School of Medicine and an honorary visiting senior fellow at the University of Cambridge, UK and has served as a Consultant to Allergan, Astra Zeneca, BioMarin, BioVail, Boehringer Ingelheim, Bristol Myers‐Squibb, Cenerex, Covance, Cypress Bioscience, Dianippon, Eisai, Eli Lilly, Forest, GlaxoSmith Kline, Labopharm, Lundbeck, Marinus, Meda Corp, Meiji, Merck, Novartis, Pfizer, Pfizer Canada, Pierre Fabre, PamLab, Prexa Pharmaceuticals, Propagate Pharma, Royalty Pharma, Sanofi, Schering Plough Corporation, Shire, SK Corporation, Soffinova, Solvay, Vanda and Wyeth. He has served on speakers bureaus for Pfizer Inc; Wyeth Pharmaceuticals and Schering Plough Corporation and has received research and/or grant support from Astra Zeneca, Boehringer Ingelheim, Bristol Myers‐Squibb, Cephalon, Dainippon, Eli Lilly, Forest, Lundbeck, Novartis, PamLabs, Pfizer, Pfizer Canada, Pharmasquire, Sanofi Aventis, Schering Plough, Shire and Wyeth.

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Citrome L, Jaffe A, Levine J. Dosing of second generation antipsychotic medication in a state hospital system. J Clin Psychopharm 2005;25:388–390. - PubMed
    1. Citrome L, Volavka J. Optimal dosing of atypical antipsychotics in adults: A review of the current evidence. Harv Rev Psychiatry 2002;10:280–291. - PubMed
    1. Olanzapine (ZyprexaTM) FDA Package Insert.
    1. Quetiapine (SeroquelTM) FDA Package Insert.
    1. Aripiprazole (AbilifyTM) FDA Package Insert.

MeSH terms

Substances